Juan C Sáez Selected Research

Proteins (Proteins, Gene)

10/2021	Anti-parasitic drugs modulate the non-selective channels formed by connexins or pannexins.
1/2020	Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation.
1/2020	Myofibers deficient in connexins 43 and 45 expression protect mice from skeletal muscle and systemic dysfunction promoted by a dysferlin mutation.
10/2019	De novo expression of functional connexins 43 and 45 hemichannels increases sarcolemmal permeability of skeletal myofibers during endotoxemia.
1/2017	Connexins and Pannexins in Bone and Skeletal Muscle.
11/2016	Connexin hemichannels explain the ionic imbalance and lead to atrophy in denervated skeletal muscles.
1/2014	Pannexin 1 channels: new actors in the regulation of catecholamine release from adrenal chromaffin cells.
2/2009	Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.
6/2007	Inflammatory conditions induce gap junctional communication between rat Kupffer cells both in vivo and in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juan C Sáez Research Topics

Disease

13	Atrophy 01/2023 - 08/2012
12	Inflammation (Inflammations) 08/2023 - 06/2002
7	Neuroinflammatory Diseases 01/2024 - 01/2013
7	Ischemia 07/2015 - 01/2002
6	Muscular Atrophy (Muscle Atrophy) 01/2020 - 08/2012
5	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2023 - 02/2009
5	Spinal Cord Injuries (Spinal Cord Injury) 02/2023 - 12/2010
5	Hypoxia (Hypoxemia) 09/2019 - 02/2010
3	Wounds and Injuries (Trauma) 02/2023 - 07/2015
3	Epilepsy (Aura) 11/2022 - 01/2018
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 08/2012
3	Inborn Genetic Diseases (Disease, Hereditary) 04/2014 - 06/2005
2	Contusions 02/2023 - 01/2023
2	Muscular Dystrophies (Muscular Dystrophy) 02/2022 - 01/2016
2	Hearing Loss (Hearing Impairment) 01/2022 - 01/2014
2	Keratitis, Ichthyosis, and Deafness (KID) Syndrome 01/2022 - 05/2015
2	Demyelinating Diseases (Demyelinating Disease) 01/2020 - 01/2017
2	Dysferlinopathy 01/2020 - 01/2016
2	Shock 10/2019 - 09/2012
2	Neoplasms (Cancer) 09/2019 - 06/2007
2	Brain Injuries (Brain Injury) 01/2018 - 01/2015
2	Pathologic Processes 01/2014 - 03/2013
1	Gout 05/2023
1	Central Nervous System Diseases (CNS Diseases) 05/2023
1	Glioblastoma (Glioblastoma Multiforme) 01/2023
1	Temporal Lobe Epilepsy 11/2022
1	Skin Diseases (Skin Disease) 01/2022
1	Drug Resistant Epilepsy 01/2022
1	Sudden Unexpected Death in Epilepsy 01/2022
1	Deafness (Deaf Mutism) 01/2022
1	Polyps 01/2022
1	Ichthyosis (Xeroderma) 01/2022
1	Keratitis 01/2022
1	Parasitic Diseases (Parasitic Disease) 10/2021
1	Brain Diseases (Brain Disorder) 01/2021
1	Weight Loss (Weight Reduction) 06/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 06/2020
1	Atherosclerosis 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Atherosclerotic Plaque (Atheroma) 01/2020
1	Diabetes Mellitus 01/2020
1	Endotoxemia 10/2019
1	Prostatic Neoplasms (Prostate Cancer) 09/2019
1	Chronic Renal Insufficiency 09/2019
1	Fibrosis (Cirrhosis) 09/2019
1	Immediate Hypersensitivity 01/2019
1	Chronic Disease (Chronic Diseases) 08/2018

Drug/Important Bio-Agent (IBA)

28	ConnexinsIBA 01/2024 - 06/2002
27	Connexin 43 (Connexin43)IBA 06/2020 - 01/2002
10	Adenosine Triphosphate (ATP)IBA 02/2023 - 02/2009
9	Proteins (Proteins, Gene)FDA Link 10/2021 - 06/2007
8	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 12/2007
7	boldineIBA 02/2023 - 01/2013
4	Glutamic Acid (Glutamate)FDA Link 02/2023 - 01/2015
3	Anticonvulsants (Antiepileptic Drugs)IBA 05/2023 - 01/2022
3	AlkaloidsIBA 01/2023 - 01/2013
3	Ion Channels (Ion Channel)IBA 01/2022 - 08/2015
3	GlucocorticoidsIBA 06/2020 - 10/2016
3	Coloring Agents (Dyes)IBA 01/2019 - 01/2002
2	Anti-Bacterial Agents (Antibiotics)IBA 05/2023 - 01/2014
2	Connexin 26IBA 01/2022 - 05/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2021 - 06/2007
2	Dexamethasone (Maxidex)FDA LinkGeneric 06/2020 - 10/2016
2	DysferlinIBA 01/2020 - 01/2016
2	LipopolysaccharidesIBA 10/2019 - 06/2002
2	AntigensIBA 01/2019 - 06/2007
2	InflammasomesIBA 01/2017 - 01/2017
2	Oxygen (Dioxygen)IBA 07/2015 - 09/2009
2	Peptides (Polypeptides)IBA 09/2011 - 02/2010
2	Ethidium (Ethidium Bromide)IBA 12/2010 - 01/2002
2	lucifer yellowIBA 12/2010 - 01/2002
1	Uricosuric AgentsIBA 05/2023
1	Probenecid (Benemid)FDA LinkGeneric 05/2023
1	Streptozocin (Streptozotocin)FDA Link 01/2023
1	Conditioned Culture MediaIBA 01/2022
1	Biopolymers (Biopolymer)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	PolyphosphatesIBA 01/2022
1	Virulence Factors (Pathogenicity Factors)IBA 01/2022
1	Glial Fibrillary Acidic ProteinIBA 10/2021
1	CalciumIBA 10/2021
1	Sucrose (Saccharose)IBA 10/2021
1	Apolipoproteins E (ApoE)IBA 02/2021
1	Complement C3 (C3 Complement)IBA 02/2021
1	MicroRNAs (MicroRNA)IBA 02/2021
1	CytokinesIBA 02/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Cholinergic ReceptorsIBA 01/2020
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2020
1	Protein Subunits (Protein Subunit)IBA 09/2019
1	thiobarbituric acidIBA 09/2019
1	Collagen Type III (Type III Collagen)IBA 09/2019
1	Immunoglobulin E (IgE)IBA 01/2019
1	Purinergic Receptors (Receptors, Purine)IBA 01/2018

Therapy/Procedure

6	Denervation 01/2020 - 10/2013
2	Therapeutics 01/2022 - 10/2019
1	Injections 08/2023
1	Complementary Therapies (Alternative Medicine) 01/2022
1	Drug Therapy (Chemotherapy) 09/2019